TrialLipids in health and disease2011

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.

Michel Farnier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.